Fig. 3: LVRNA001 provided protection against various RABV strains in pre- and post-exposure mouse models.
From: Safety and efficacy assessment of an mRNA rabies vaccine in dogs, rodents, and cynomolgus macaques
a Schematic diagram depicting the experimental procedure for pre-exposure treatment schedule for mice. Mice were vaccinated i.m. with LVRNA001 (1.67 μg or 5 μg, 0d or 0d/7d), or inactivated vaccine (1/10 or 1/30 human use, 0d/7d). Then, they were challenged i.m. with 50-fold LD50 of RABVs (SC16, GD1, NM3, QH2, LY, YN3, and XZ17, belonging to China I–VII clades, respectively) on D14 after vaccination. b Animal survival was calculated on D42. c Schematic diagram depicting the experimental procedure of post-exposure treatment schedule for mice. After challenge i.m. by 50-fold LD50 of different RABV clades (SC16, GD1, NM3, QH2, LY, YN3, and XZ17) for 2 h, mice were vaccinated i.m. with LVRNA001 (1.67 μg, 0d/7d or 0d/14d), LVRNA001 (5 μg, 0d/7d or 0d/14d) or inactivated vaccine (1/10 or 1/30 human use, 0d/3d/7d/14d/28d). d Animals were monitored and survival rate was evaluated on D28. n = 10.
